<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00174083</url>
  </required_header>
  <id_info>
    <org_study_id>9461700717</org_study_id>
    <nct_id>NCT00174083</nct_id>
  </id_info>
  <brief_title>Diagnosis of Active Tuberculosis by ELISPOT</brief_title>
  <official_title>Diagnosis of Active Tuberculosis in Endemic Area by Using Enzyme-Linked Immunospot Assay for Gamma-Interferon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <brief_summary>
    <textblock>
      Recent studies revealed that the ex vivo enzyme-linked immunospot (ELISPOT) assay for gamma
      interferon is a specific method for contact tracing of Mycobacterium tuberculosis infection.
      However, its use in endemic area and bacillus Calmette-Guérin (BCG)-vaccinated hosts has not
      been proved. We hypothesize that the TB-ELISPOT assay can be a rapid and accurate diagnostic
      tool for active tuberculosis in clinical suspects in Taiwan.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2005</start_date>
  <completion_date>December 2006</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Screening</primary_purpose>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Cross-Sectional, Prospective</time_perspective>
  </study_design_info>
  <enrollment>200</enrollment>
  <condition>Tuberculosis</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who present with fever or respiratory symptoms (cough, dyspnea, or
             hemoptysis) lasting for ≥ 2 weeks and have compatible radiographic findings were
             considered clinical suspects of TB.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jann-Yuan Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>physician</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jann-Yuan Wang, MD</last_name>
    <phone>886-2-23562905</phone>
    <email>jywang@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jann-Yuan Wang, MD</last_name>
      <phone>886-2-23562905</phone>
      <email>jywang@ntu.edu.tw</email>
    </contact>
    <contact_backup>
      <last_name>Li-Na Lee, PhD</last_name>
      <phone>886-2-23563905</phone>
      <email>linalee@ntu.edu.tw</email>
    </contact_backup>
    <investigator>
      <last_name>Jann-Yuan Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Wilkinson RJ, Vordermeier HM, Wilkinson KA, Sjölund A, Moreno C, Pasvol G, Ivanyi J. Peptide-specific T cell response to Mycobacterium tuberculosis: clinical spectrum, compartmentalization, and effect of chemotherapy. J Infect Dis. 1998 Sep;178(3):760-8.</citation>
    <PMID>9728545</PMID>
  </reference>
  <reference>
    <citation>Wilkinson KA, Wilkinson RJ, Pathan A, Ewer K, Prakash M, Klenerman P, Maskell N, Davies R, Pasvol G, Lalvani A. Ex vivo characterization of early secretory antigenic target 6-specific T cells at sites of active disease in pleural tuberculosis. Clin Infect Dis. 2005 Jan 1;40(1):184-7. Epub 2004 Dec 8.</citation>
    <PMID>15614710</PMID>
  </reference>
  <reference>
    <citation>Ulrichs T, Munk ME, Mollenkopf H, Behr-Perst S, Colangeli R, Gennaro ML, Kaufmann SH. Differential T cell responses to Mycobacterium tuberculosis ESAT6 in tuberculosis patients and healthy donors. Eur J Immunol. 1998 Dec;28(12):3949-58. Erratum in: Eur J Immunol 1999 Feb;29(2):725.</citation>
    <PMID>9862331</PMID>
  </reference>
  <reference>
    <citation>Ulrichs T, Anding R, Kaufmann SH, Munk ME. Numbers of IFN-gamma-producing cells against ESAT-6 increase in tuberculosis patients during chemotherapy. Int J Tuberc Lung Dis. 2000 Dec;4(12):1181-3.</citation>
    <PMID>11144463</PMID>
  </reference>
  <reference>
    <citation>Torres M, Herrera T, Villareal H, Rich EA, Sada E. Cytokine profiles for peripheral blood lymphocytes from patients with active pulmonary tuberculosis and healthy household contacts in response to the 30-kilodalton antigen of Mycobacterium tuberculosis. Infect Immun. 1998 Jan;66(1):176-80.</citation>
    <PMID>9423855</PMID>
  </reference>
  <reference>
    <citation>Skjøt RL, Oettinger T, Rosenkrands I, Ravn P, Brock I, Jacobsen S, Andersen P. Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect Immun. 2000 Jan;68(1):214-20.</citation>
    <PMID>10603390</PMID>
  </reference>
  <reference>
    <citation>Schluger NW, Rom WN. The host immune response to tuberculosis. Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):679-91. Review.</citation>
    <PMID>9517576</PMID>
  </reference>
  <reference>
    <citation>Richeldi L, Ewer K, Losi M, Bergamini BM, Roversi P, Deeks J, Fabbri LM, Lalvani A. T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure. Am J Respir Crit Care Med. 2004 Aug 1;170(3):288-95. Epub 2004 May 6.</citation>
    <PMID>15130907</PMID>
  </reference>
  <reference>
    <citation>Ravn P, Demissie A, Eguale T, Wondwosson H, Lein D, Amoudy HA, Mustafa AS, Jensen AK, Holm A, Rosenkrands I, Oftung F, Olobo J, von Reyn F, Andersen P. Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J Infect Dis. 1999 Mar;179(3):637-45.</citation>
    <PMID>9952370</PMID>
  </reference>
  <reference>
    <citation>Pollock JM, Andersen P. The potential of the ESAT-6 antigen secreted by virulent mycobacteria for specific diagnosis of tuberculosis. J Infect Dis. 1997 May;175(5):1251-4.</citation>
    <PMID>9129098</PMID>
  </reference>
  <verification_date>July 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>September 13, 2005</last_update_submitted>
  <last_update_submitted_qc>September 13, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2005</last_update_posted>
  <keyword>Tuberculosis, TB-ELISPOT, active tuberculosis latent infection interferon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

